The steady stream of IPOs…
The steady stream of IPOs evaporated almost as quickly as [...]
Terremoto Biosciences has spelt…
Terremoto Biosciences has spelt out how the California biotech will [...]
Travere is eyeing a collective $3…
Travere is eyeing a collective $3 billion U.S. opportunity for [...]
Even as Eli Lilly gets underway…
Even as Eli Lilly gets underway with its next major [...]
Protagonist Therapeutics-partnered…
Protagonist Therapeutics-partnered Icotyde has the potential to become one of [...]
After initiating a wind-down more…
After initiating a wind-down more than 18 months ago and [...]
Astellas is preparing to close its…
Astellas is preparing to close its Seattle site for its [...]
Takeda has pulled back from a…
Takeda has pulled back from a research collaboration with a [...]
F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials
Many unfavorable results go unreported, skewing the available data on [...]
An FDA review of records found…
An FDA review of records found that results have not [...]